The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of the COVID-19 pandemic on stage at diagnosis of patients with breast cancer: An analysis of 11,752 patients from Oncoclínicas.
 
Cristiano Augusto Andrade de Resende
Honoraria - BMS Brazil; Daiichi Sankyo/Astra Zeneca; MSD Oncology; Novartis; Pfizer; Roche
 
Rodrigo Dienstmann
Employment - Oncoclínicas
Consulting or Advisory Role - Boehringer Ingelheim; Roche
Speakers' Bureau - Amgen; Ipsen; Libbs; MSD Oncology; Roche; Sanofi; SERVIER
Research Funding - Merck
 
Carlos H. Barrios
Stock and Other Ownership Interests - MedSIR; Tummi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Eisai; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Zodiac Pharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Eisai; GlaxoSmithKline; Libbs; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Research Funding - AB Science (Inst); Abbvie (Inst); Abraxis BioScience (Inst); Amgen (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clinica Atlantis (Inst); Covance (Inst); Daiichi Sankyo (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); ImClone Systems (Inst); INC Research (Inst); inVentiv Health (Inst); Janssen (Inst); LEO Pharma (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merrimack (Inst); Millennium (Inst); Mylan (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Polyphor (Inst); Roche/Genentech (Inst); Sanofi (Inst); Shanghai Henlius Biotech (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Bruno Lemos Ferrari
No Relationships to Disclose
 
Aline Coelho Goncalves
Consulting or Advisory Role - Lilly; Novartis; Novartis; Pfizer; United Medical
Speakers' Bureau - AstraZeneca/Daiichi Sankyo; Lilly; Novartis; Pfizer
 
Fanny Cascelli
Travel, Accommodations, Expenses - Grupo Oncoclinicas (Inst)
 
Andreza Karine Souto
No Relationships to Disclose
 
Matheus Costa e Silva
Employment - Grupo Oncoclínicas; Rede D'Or São Luiz
 
Heloisa Cruz
No Relationships to Disclose
 
Leandro Carvalho Oliveira
No Relationships to Disclose
 
Diocesio Alves Pinto de Andrade
No Relationships to Disclose
 
Eduardo Camargo Millen
Honoraria - Roche
 
Felipe Zerwes
Honoraria - Roche
Consulting or Advisory Role - MSD
 
Tomas Reinert
Honoraria - AstraZeneca; Libbs; Lilly; Novartis; Pfizer; Pierre Fabre
Consulting or Advisory Role - Lilly; Novartis
Research Funding - AstraZeneca (Inst); Libbs (Inst)
 
Paulo Moraes
Honoraria - Varian Medical Systems
 
Max S. Mano
Employment - Grupo Oncoclinicas
Stock and Other Ownership Interests - Fleury Group; Hypera Pharma
Honoraria - DASA; Grupo Fleury; Lilly/ImClone; MSD Oncology; Novartis; Oncologia Brasil; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Lilly/ImClone; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
(OPTIONAL) Uncompensated Relationships - Roche